BioNTechBNTX
BNTX
About: BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates, or ADCs. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. Covid vaccine Comirnaty is its first commercialized product.
Employees: 6,772
0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 5 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
39% more call options, than puts
Call options by funds: $373M | Put options by funds: $269M
29% more first-time investments, than exits
New positions opened: 63 | Existing positions closed: 49
10% more capital invested
Capital invested by funds: $5.24B [Q3] → $5.78B (+$544M) [Q4]
2.74% more ownership
Funds ownership: 18.6% [Q3] → 21.34% (+2.74%) [Q4]
2% more funds holding
Funds holding: 293 [Q3] → 299 (+6) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 7 [Q3] → 7 (+0) [Q4]
1% less repeat investments, than reductions
Existing positions increased: 84 | Existing positions reduced: 85
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$139
33%
upside
Avg. target
$149
43%
upside
High target
$171
65%
upside
5 analyst ratings
5 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Robert Burns 27% 1-year accuracy 46 / 173 met price target | 39%upside $145 | Buy Maintained | 1 Apr 2025 |
Citigroup Geoff Meacham 45% 1-year accuracy 15 / 33 met price target | 39%upside $145 | Buy Initiated | 13 Mar 2025 |
Morgan Stanley Terence Flynn 50% 1-year accuracy 11 / 22 met price target | 33%upside $139 | Overweight Maintained | 11 Mar 2025 |
Canaccord Genuity John Newman 30% 1-year accuracy 8 / 27 met price target | 65%upside $171 | Buy Maintained | 11 Mar 2025 |
BMO Capital Etzer Darout 30% 1-year accuracy 10 / 33 met price target | 37%upside $143 | Outperform Maintained | 11 Mar 2025 |
Financial journalist opinion
Based on 6 articles about BNTX published over the past 30 days
Negative
The Motley Fool
5 days ago
Why Biotech Stars Summit Therapeutics and BioNTech Plunged, Even as This Chinese Rival Surged Today
Shares of biotech companies involved in the development of monoclonal antibody cancer therapies were moving all over the place on Friday. Both U.S.-based Summit Therapeutics (SMMT -36.19%) and BioNTech (BNTX -15.40%) were down significantly, plunging 36.1% and 15.4%, respectively, in Friday's trading.
Neutral
GlobeNewsWire
6 days ago
BioNTech to Present Clinical and Preclinical Data Across mRNA and Next-Generation Immuno-Oncology Priority Programs at AACR 2025
MAINZ, Germany, April 24, 2025 -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present data for selected assets from its diversified oncology pipeline, including mRNA cancer immunotherapies, next-generation immunomodulators, and targeted therapies, at the American Association for Cancer Research (“AACR”) Annual Meeting held in Chicago, Illinois from April 25-30, 2025. The oral and poster presentations underline both the progress of BioNTech's advanced priority oncology programs as well as the execution of the Company's combination strategy in oncology, with first data to be presented for the combination of the PD-L1xVEGF-A bispecific antibody candidate BNT3271 plus antibody-drug conjugates (“ADCs”).
Positive
Investors Business Daily
1 week ago
BioNTech Surges On Summit's Coattails. But Can They Take On Merck?
BioNTech stock rocketed Wednesday after rival Summit Therapeutics unveiled promising results for a novel approach to lung cancer treatment.
Neutral
GlobeNewsWire
1 week ago
BioNTech to Report First Quarter 2025 Financial Results and Corporate Update on May 5, 2025
MAINZ, Germany, April 22, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the first quarter 2025 on Monday, May 5, 2025. Additionally, the Company will host a conference call and webcast that day at 8:00 a.m. EDT (2:00 p.m. CEST) for investors, financial analysts and the general public to discuss its financial results and provide a corporate update.
Positive
Zacks Investment Research
2 weeks ago
Strength Seen in BioNTech (BNTX): Can Its 6.0% Jump Turn into More Strength?
BioNTech (BNTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Neutral
Investors Business Daily
2 weeks ago
Trump Wants RFK Jr. To 'Go Wild' On Health Care. What This Means For Biotech Stocks.
Robert F. Kennedy Jr. is the new Health Secretary. From fluoride, vaccines and beef tallow, here's how he might "go wild" on biotech stocks.
Negative
CNBC Television
4 weeks ago
Vaccine stocks fall following FDA resignation
Dr. Kavita Patel joins 'Fast Money' to talk the impact of FDA and HHS changes on vaccines, public health policy, and more.
Negative
Fast Company
4 weeks ago
Vaccine stocks tumble: Moderna, Novavax, Pfizer fall after top FDA official resigns over RFK Jr. anti-vax views
Stocks of major vaccine makers dropped on Monday after the Food and Drug Administration's (FDA) top vaccine official Dr. Peter Marks resigned, citing conflicts with Health and Human Services (HHS) Secretary Robert F. Kennedy (RFK) Jr. over his views on immunization.
Negative
New York Post
4 weeks ago
Drug stocks sink as FDA's top vaccine official is ousted in Trump overhaul
Shares of U.S. drugmakers fell on Monday after reports that the Food and Drug Administration's top vaccine official was forced to resign, the most high-profile exit at the regulator as the Trump administration undertakes an overhaul of federal health agencies.
Negative
CNBC
1 month ago
Vaccine stocks fall after key FDA official resigns in protest of RFK Jr.
Shares of vaccine makers Moderna and Novavax, along with a range of other biotech companies, fell after the resignation of key FDA official Peter Marks. Marks stepped down in protest of Health and Human Services Secretary Robert F.
Charts implemented using Lightweight Charts™